Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$139 Mln
P/E Ratio
--
P/B Ratio
52.28
Industry P/E
28.06
Debt to Equity
0
ROE
-3.42 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-18.53 Mln
EBITDA
$-28.92 Mln
Net Profit
$-28.02 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Greenwich Lifesciences Inc (GLSI)
| -10.60 | -6.26 | -24.40 | -23.48 | -8.46 | -- | -- |
|
BSE Sensex*
| 2.70 | 3.81 | 5.88 | 8.99 | 11.79 | 20.14 | 11.36 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Greenwich Lifesciences Inc (GLSI)
| 6.69 | -30.79 | -37.53 | -33.29 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.89 | 6,904.81 | -- | 38.11 | |
| 70.95 | 7,574.08 | 58.3 | 23.56 | |
| 59.52 | 11,448.88 | 394.4 | 0.76 | |
| 8.25 | 9,704.70 | -- | -3.24 |
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III... clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas. Read more
CEO, CFO & Director
Mr. Snehal S. Patel
CEO, CFO & Director
Mr. Snehal S. Patel
Headquarters
Stafford, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Greenwich Lifesciences Inc (GLSI) stood at $ 8 Mln as on 31-Mar-25
The share price of Greenwich Lifesciences Inc (GLSI) is $10.04 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Greenwich Lifesciences Inc (GLSI) has given a return of -8.46% in the last 3 years.
Greenwich Lifesciences Inc (GLSI) has a market capitalisation of $ 139 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Greenwich Lifesciences Inc (GLSI) is 52.28 times as on 25-Apr-2025, a 937% premium to its peers’ median range of 5.04 times.
Since, TTM earnings of Greenwich Lifesciences Inc (GLSI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Greenwich Lifesciences Inc (GLSI) and enter the required number of quantities and click on buy to purchase the shares of Greenwich Lifesciences Inc (GLSI).
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
The CEO & director of Mr. Snehal S. Patel. is Greenwich Lifesciences Inc (GLSI), and CFO & Sr. VP is Mr. Snehal S. Patel.
There is no promoter pledging in Greenwich Lifesciences Inc (GLSI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Greenwich Lifesciences Inc (GLSI) | Ratios |
|---|---|
|
Return on equity(%)
|
-568.22
|
|
Operating margin(%)
|
-373051.38
|
|
Net Margin(%)
|
-591246.76
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Greenwich Lifesciences Inc (GLSI) was $0 Mln.
$0.06
(
